<code id='6FBFBA70AF'></code><style id='6FBFBA70AF'></style>
      • <acronym id='6FBFBA70AF'></acronym>
      <center id='6FBFBA70AF'><center id='6FBFBA70AF'><tfoot id='6FBFBA70AF'></tfoot></center><abbr id='6FBFBA70AF'><dir id='6FBFBA70AF'><tfoot id='6FBFBA70AF'></tfoot><noframes id='6FBFBA70AF'>
      • <optgroup id='6FBFBA70AF'><strike id='6FBFBA70AF'><sup id='6FBFBA70AF'></sup></strike><code id='6FBFBA70AF'></code></optgroup>
        5. <b id='6FBFBA70AF'><label id='6FBFBA70AF'><select id='6FBFBA70AF'><dt id='6FBFBA70AF'><span id='6FBFBA70AF'></span></dt></select></label></b><u id='6FBFBA70AF'></u>
          <i id='6FBFBA70AF'><strike id='6FBFBA70AF'><tt id='6FBFBA70AF'><pre id='6FBFBA70AF'></pre></tt></strike></i>
           


   

   

   
   
   
   
   
   
   
   
   
   
   
   
   

   
   
   
   
   
   
   
  
           
  
           
  
           
   
           
    
           
     
           
      
           
       
      
           
      
           
       
           
        
           
         
           
           
          
           
         
           
         
           
           
          
           
         
           
          
        
           
       
           
       
           
        
           
        
           
        
           
        
           
       
           
      
           
       
      
           
      
           
       
           
       
           
       
           
       
           
        
           
        
          
          00:00 
        
           
       
           
       
           
      
           
      
           
        
        
        
       
           
        00:00 
         
        00:00 
        LIVE 
       
           
        
       
           
        
           
        
           
        
           
        
           
       
           
       
           
       
           
        
        
        
        
        
        
        
        
        
      
           
       
    
    
      
           
       
           
      
           
     
           
     
           
       
     
           
     
           
      
           
      
           
      
           
      
           
       
           
      
           
      
           
      
           
       
           
       
          
         buffering 
       
           
      
           
      
           
       
           
        
           
        
          
          Replay 
        
           
       
           
      
           
       
      
           
      
           
       
           
       
           
        
           
        
           
        
           
       
           
      
           
      
           
      
           
      
           
      
           
       
           
      
           
     
           
     
           
      
           
     
           
     
           
      
           
       
           
        
           
       
           
       
           
        
          
          LIVE 
        
           
        00:00 
         /  
        00:00 
       
           
       
           
        
           
        
           
        
           
         
           
         
           
         
           
         
           
         
           
         
           
        
           
        
           
        
           
       
           
       
           
        
           
        
          
          LIVE 
        
           
       
           
       
           
        
           
        
          
          CC 
        
           
       
           
       
           
        
           
       
           
       
           
       
           
        
           
        
           
         
           
        
           
       
           
       
           
        
           
       
           
      
           
      
           
       
           
        
           
        
           
         
           
         
           
         
           
          
           
          
           
          
           
         
           
        
           
       
           
      
           
      
           
       
           
     
       
           
    
       
           
       
    
  
       
           
   
       
           
       
       
           
      
           
      
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       Opacity : 
        
      
           
     
           
     
           
     
           
      
           
  
     
           
    
           
    
           
    
           
     
          
       Share: 
     
           
      
     
           
      
      Copy 
     
           
      
    
           
    
          
      Close 
      
    
           
    
           
      
    
           
    
           
   
           
  
           
  
           
    
    
    
   
           
   
           
 
    
   
           
   
           
   
           
    
           
     
           
      
           
       
           
        
           
          
          
         
          
          focus 

          
          
            
          
          

           
           
        
           
       
           
      
           
     
           
    
           
    
           
     
           
      
           
      
           

                       
          focus  
          
                                   
                 
                                      author：entertainment   
                                        
                                      
                                      -
 
browse：667
                                  
                                    
          
                                    
            
          
 
          Illustration fo a pink arrow pointing downward. -- biotech coverage from STAT
          Adobe
          SAN DIEGO — Ventyx Biosciences reported on Monday that it was ending development of an experimental drug for treating plaque psoriasis though it proved safe and moderately effective in a mid-stage trial. Within hours, the company’s stock tanked by more than 80%.
          That’s because the company announced that the small molecule, VTX958, had not met the biotech’s internal goals to advance to the next phase of clinical development. Ventyx said it would end work on the drug, which targets the signaling molecule TYK2, as a treatment for psoriasis and psoriatic arthritis.
          advertisement
          Shares in Ventyx plummeted from $14.09 at market close to as little as $2.72 during after-hours trading. In the process, the company’s market value dropped from $830 million to around $160 million. Ventyx is now trading below its cash balance, which was $300 million as of the end of September.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe													Log In											
           
 
 
          

                              
          
                                 Previous article：

                                
                                          Hepatitis C has a cure — but many Americans still lack access to it
                                
                            
          Next article：  
                                      
                                          JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc
                                                                    
          

      
           
      
           
        
           
                                               
        
           entertainment 
           
                   
      
           
  
  
          
    
          
        
          
            
          
                                                     
                
          explore
          
                            
          
        
          
        
    
          

          

    

      
           
     
           


   
    
           
   
           
  
 

  
           
    
           
           
           
            
            Back To Top 
           
           
           
           

            
           
                                                                    
                 
          focus
           
                                      
            
           
          
           
                                                          
             
          hotspot
           
                             
            
           
            
           

                                                         
             
          entertainment
           
               
              
            
           
            
           
                                                         
             
          Wikipedia
           
                             
      
           
 
     
           
     
           
      
          
              AdobeWASHINGTON— UCBleftBIOattheendof2023,thesecondmajormembercompanytoexitafterPfizerpulledoutaswel
             
           
      
          
        © 2013-2023.Company name All rights reserved.Site Map 
         WSS-More Templates  
             Guangdong ICP46name